In the last trading session, 20.62 million shares of the Plus Therapeutics Inc (NASDAQ:PSTV) were traded, and its beta was 0.56. Most recently the company’s share price was $1.14, and it changed around -$0.04 or -3.39% from the last close, which brings the market valuation of the company to $13.43M. PSTV currently trades at a discount to its 52-week high of $2.67, offering almost -134.21% off that amount. The share price’s 52-week low was $0.24, which indicates that the current value has risen by an impressive 78.95% since then. We note from Plus Therapeutics Inc’s average daily trading volume that its 10-day average is 44.6 million shares, with the 3-month average coming to 15.06 million.
Plus Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended PSTV as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Plus Therapeutics Inc is expected to report earnings per share of -0.5 for the current quarter.
Plus Therapeutics Inc (NASDAQ:PSTV) trade information
Instantly PSTV has showed a red trend with a performance of -3.39% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.0800 on recent trading dayincreased the stock’s daily price by 45.19%. The company’s shares are currently down -0.87% year-to-date, but still up 94.54% over the last five days. On the other hand, Plus Therapeutics Inc (NASDAQ:PSTV) is -5.00% down in the 30-day period. We can see from the shorts that 0.14 million shares have been sold at a short interest cover period of 1.23 day(s).
Plus Therapeutics Inc (PSTV) estimates and forecasts
The year-over-year growth rate is expected to be 12.52%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 1.01M in revenue for the current quarter. 3 analysts expect Plus Therapeutics Inc to make 1.38M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.31M and 1.68M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -23.33%. Forecasts for the next quarter put sales growth at -17.51%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 68.20%. Plus Therapeutics Inc earnings are expected to increase by 56.01% in 2025, but the outlook is positive 33.56% per year for the next five years.
Plus Therapeutics Inc (NASDAQ:PSTV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 17.36% of Plus Therapeutics Inc shares, and 11.50% of them are in the hands of institutional investors. The stock currently has a share float of 13.92%.
Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 34.96 shares worth $39849.0, making up 0.30% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 32.54 shares worth around $37096.0, which represents about 0.28% of the total shares outstanding.
